Aadi bioscience announces improved anti-tumor activity of kras inhibitors in combination with nab-sirolimus at the 34th eortc-nci-aacr symposium

Poster presentation scheduled for october 27, 2022 los angeles , oct. 12, 2022 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced that preclinical combination data of kras inhibitors and nab-sirolimus will be presented during a poster session at the upcoming 34th eortc-nci-aacr symposium, taking place october 26-28, 2022 in barcelona, spain. nab-sirolimus is a novel albumin-bound nanoparticle form of the mtor inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma).
AADI Ratings Summary
AADI Quant Ranking